Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide
复制标题
DOI：
10.1080/10428190903040006
复制
发表时间：
2009-01-01
影响因子：
2.6
通讯作者：
Tomas, Jose F.
中科院分区：
文献类型：
--
作者：
Martinez-Lopez, Joaquin;Rivero, Ana;Tomas, Jose F.
目前基于化疗和免疫治疗的治疗方法的使用导致免疫抑制。与免疫系统相关的基因中的突变或多态性的存在可能涉及额外的缺点。本研究的目的是分析甘露糖结合凝集素（MBL-2基因）突变及其与临床试验LNHF-03中诊断为滤泡性淋巴瘤并接受统一治疗的患者的严重感染和无事件生存率的相关性。这项试验的结果显示了令人印象深刻的临床疗效，但并发了80例记录在案的感染事件。根据单倍型遗传，将患者分为AA和AO/OO两个基因型组。没有发现感染发作次数和无事件生存率的差异是MBL-2组的函数。其他因素，包括恶性淋巴瘤和与疾病相关的免疫改变，应被认为是造成这一观察结果的原因。
The employment of current treatments based on chemotherapy and immunotherapy leads to inmunosuppression. The presence of mutations or polymorphisms in genes related to immune system might involve an additional disadvantage. The aim of the present study was to analyze mannose-binding lectin (MBL-2 gene) mutations and their association with severe infections and event-free survival in patients diagnosed with follicular lymphoma, treated uniformly, in the clinical trial LNHF-03. The results of this trial showed impressive clinical efficacy but was complicated with 80 documented infectious episodes. Patients were classified into two genotypic groups, AA and AO/OO, based on their haplotypic inheritance. Neither the number of infectious episodes nor differences in event-free survival was found as a function of MBL-2 groups. Other factors, including the lymphoma malignancy and the immune alterations associated with the disease, should be considered responsible for this observation.